| Literature DB >> 31632272 |
Wei-Jian Zhang1, Wei-Wei Su1,2, Pei-Bo Li1, Hong-Yu Rao1, Qing-Wei Lin1, Xuan Zeng1, Tao-Bin Chen1, Zeng-Hao Yan1, Hong Liu1, Hong-Liang Yao1,3.
Abstract
Naoxintong capsule (NXT), a Chinese medicine, has performed excellent effects on the prevention and treatment against cardiovascular diseases. NXT is a fine powder mixture without any herb extraction, and there must be lots of ingredients hard to be absorbed. However, little is known about the correlation between the NXT's cardioprotective effects and gut microbiota. Herein, we report the effect of NXT on the development of cardiovascular diseases and clarify the correlation between NXT's cardioprotective effects and gut microbiota. In the current study, minipigs were selected and fed with high-fat diet and NXT daily for successive 8 months. During the process, up to 18 biomedical parameters were monthly determined to observe the dynamic changes after NXT treatment. At the end of experimental process, pathological examinations of heart, coronary artery, carotid artery, thoracic aorta, and abdominal aorta were conducted by HE staining and 16SrDNA sequencing, and analyzing of gut microbiota were conducted. Our results showed that NXT's effects against cardiovascular diseases were through regulating blood lipid profiles, inhibiting vascular inflammation, enhancing antioxidant capacity, and alleviating myocardial injury, without damages on liver and kidney particularly. Concurrently, we also found that long-term administration of NXT increased the diversity of gut microbiota, influenced the microbiome structure and composition stably, and revered the increase of the ratio of the Firmicutes to Bacteroidetes (F/B ratio) in relative abundance. Specifically, our results revealed some key bacterium of Caproiciproducens (enhanced), Sutterella (enhanced), Erysipelotrichaceae (enhanced), and Romboutsia (decreased) that were closely involved in NXT's effects. Taken together, our study demonstrates that NXT can inhibit the development of cardiovascular diseases by ameliorating high-fat diet-induced metabolic disorders and partly through improving gut microbiota.Entities:
Keywords: Bama minipig; Naoxintong capsule (NXT); blood lipid metabolism; cardiovascular diseases; gut microbiota
Year: 2019 PMID: 31632272 PMCID: PMC6785636 DOI: 10.3389/fphar.2019.01128
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Identification of the chemical constituents of NXT by UFLC-Q-TOF-MS/MS.
|
| Formula | [M+H]+
| [M−H]−
| Fragment ions in positive (+) ion mode | Fragment ions in negative (−) ion mode | Identification |
|---|---|---|---|---|---|---|
| 4.02 | C10H13N5O4 | 268.1043 (1) | 136.0644[M+H−C5H2N5]+ | Adenosine | ||
| 5.03 | C7H6O5 | 169.0151 (5.2) | 125.0243[M−H−C2H4O]− | Gallic acid | ||
| 12.21 | C19H28O11 | 431.1559 (0.1) | 269.1029[M−H−C6H10O5]− | Benzyl-β-gentiobioside | ||
| 12.22 | C26H32O14 | 567.1721 (0.2) | 405.1124[M−H−C6H10O5]−, 243.0652[M−H−2C6H10O5]− | Mulberroside A | ||
| 13.05 | C23H28O12 | 495.1511 (0.5) | 333.1036[M−H−C6H10O5]− | Oxypaeoniflorin | ||
| 13.39 | C7H6O3 | 137.0260 (10) | 108.0206[M−H−CHO]− | Protocatechuic aldehyde | ||
| 13.91 | C16H18O9 | 353.0883 (1.1) | 191.0573[M−H−C6H10O5]− | Chlorogenic acid | ||
| 14.27 | C15H14O6 | 291.0866 (0.9) | 289.0721 (1.3) | 165.0565[M+H−C6H6O3]+, 139.0401[M+H−C8H6O3]+, 123.0477[M+H−C8H7O4]+ | 245.0859[M−H−CO2]−, 203.0734[M−H−CO2−C2H2O]−, 161.0602[M−H−CO2−2C2H2O]−, 151.0422[M−H−C6H6O2−CO]− | Catechin |
| 14.34 | C27H32O16 | 611.1622 (0.8) | 491.1219[M−H−C4H8O4]−, 473.0862[M−H−C4H8O4−H2O]−, 403.1008[M−H−C7H10O6−H2O]−, 325.0727[M−H−C5H8O5−H2O]−, 283.0646[M−H−C4H8O4−C7H10O6−H2O]− | Hydroxysafflor yellow A | ||
| 14.44 | C8H8O5 | 183.0308 (3.3) | 124.0148[M−H−C2H5O2]− | Methyl gallate | ||
| 15.43 | C20H27NO11 | 456.1512 (0.1) | 323.0964[M−H−C8H7NO]− | Amygdalin | ||
| 19.34 | C15H14O6 | 291.0866 (0.8) | 289.0723 (1.8) | 165.0565[M+H−C6H6O3]+, 139.0401[M+H−C8H6O3]+, 123.0477[M+H−C8H7O4]+ | 245.0832[M−H−CO2]−, 205.0552[M−H−2C2H2O]−, 203.0735[M−H−CO2−C2H2O]−, 151.0443[M−H−C6H6O2−CO]−, 125.0230[M−H−C9H8O3]− | Epicatechin |
| 20.13 | C23H28O11 | 481.1704 (0) | 479.1560 (0.3) | 197.0807[M+H−C6H10O5−C7H5O2]+, 179.0696[M+H−C6H10O5−C7H5O2−H2O]+ | 121.0311[M−H−C15H18O10]− | Albiflorin |
| 22.04 | C27H30O17 | 627.1550 (−1) | 625.1420 (1) | 465.1050[M+H−C6H10O5]+, 303.0474[M+H−2C6H10O5]+ | 463.0879[M−H−C6H10O5]−, 301.0346[M−H−2C6H10O5]− | 6-Hydroxy kaempferol-di-O-glucoside |
| 22.54 | C23H28O11 | 479.1560 (0.3) | 327.1174[M−H−C7H6O2−CH2O]−, 165.0577[M−H−C17H14O6]−, 121.0298[M−H−C16H22O9]− | Paeoniflorin | ||
| 25.12 | C27H30O16 | 611.1601 (−0.9) | 609.1471 (0.8) | 465.0915[M+H−C6H10O4]+, 303.0479[M+H−C12H20O9]+ | 301.0356[M−H−C12H20O9]−, 272.0279[M−H−C13H22O10]− | Rutin |
| 26.18 | C21H20O12 | 465.1029 (0.2) | 463.0887 (1) | 303.0490[M+H−C6H10O5]+ | 301.0365[M−H−C6H10O5]− | Isoquercitrin |
| 27.2 | C22H22O10 | 447.1285 (−0.3) | 285.0746[M+H−C6H10O5]+, 270.0514[M+H−C6H10O5−CH3]+, 253.0474[M+H−C6H10O5−CH3OH]+, 225.0520[M+H−C6H10O5−CH3OH−CO]+, 137.0250[M+H−C6H10O5−C9H8O2]+ | Calycosin-7-O-β-D-glycoside | ||
| 27.93 | C10H10O4 | 195.0650 (−0.9) | 193.0512 (3) | 177.0527[M+H−H2O]+, 149.0594[M+H−H2O−CO]+, 145.0283[M+H−H2O−CH3OH]+, 134.0390[M+H−H2O−CO−CH3]+, 117.0380[M+H−H2O−CO−CH3OH]+, 89.0445[M+H−H2O−CH3OH−2CO]+ | 178.0258[M−H−CH3]−, 134.0371[M−H−CO2]−, 89.0411[M−H−CH3−CO2]− | Ferulic acid |
| 28.45 | C27H44O7 | 481.3157 (−0.5) | 445.2911[M+H−2H2O]+, 427.2891[M+H−3H2O]+, 371.2204[M+H−3H2O−CO2]+ | β-Ecdysterone | ||
| 29.88 | C30H32O15 | 631.1679 (1.6) | 613.1554[M−H−H2O]−, 491.0970[M−H−C7H5O2−H2O]−, 313.0580[M−H−C17H16O5−H2O]− | Galloylpaeoniflorin | ||
| 31.01 | C15H12O7 | 303.0515 (1) | 285.0535[M−H−H2O]−, 125.0231[M−H−C6H4O3−3H2O]− | Taxifolin | ||
| 31.46 | C41H32O26 | 939.1140 (2.2) | 769.0530[M−H−C7H6O5]− | Pentagalloylglucose | ||
| 32.19 | C15H10O6 | 287.0551 (0.4) | 258.0529[M+H−CHO]+, 213.0552[M+H−H2O−2CO]+, 165.0163[M+H−C7H6O2]+ | Kaempferol | ||
| 32.19 | C21H20O11 | 449.1074 (−0.9) | 287.0532[M+H−C6H10O5]+ | Kaempferol-3-O-glucoside | ||
| 32.24 | C27H30O15 | 595.1653 (−0.8) | 593.1521 (0.8) | 287.0548[M+H−C12H20O9]+ | 285.0410[M−H−C12H20O9]− | Kaempferol-3-O-rutinoside |
| 33.37 | C14H12O4 | 245.0810 (0.8) | 243.0668 (2.3) | 199.0777[M+H−C2H6O]+, 181.0603[M+H−C2H6O−H2O]+, 161.0606[M+H−C4H4O2]+, 107.0544[M+H−C7H4O2−H2O]+ | 225.0572[M−H−H2O]−, 199.0766[M−H−C2H4O]−, 175.0763[M−H−C4H4O]−, 159.0459[M−H−C4H4O2]− | Oxyresveratrol |
| 35.71 | C25H24O13 | 533.1284 (−1) | 285.0759[M+H−C6H10O5−C3H2O3]+ | Calycosin-7-O-β-D-glc-6”-O-malonate | ||
| 36.01 | C9H16O4 | 187.0989 (4.5) | 125.0970[M−H−CO2−H2O]− | Skinorim | ||
| 37.33 | C9H6O2 | 147.0442 (1) | 103.0596[M+H−CO2]+, 91.0593[M+H−2CO]+, 77.0471[M+H−C3H2O2]+, 65.0479[M+H−C4H2O2]+, 51.0300[M+H−C5H4O2]+ | Coumarin | ||
| 37.56 | C18H16O8 | 359.0778 (1.6) | 197.0474[M−H−C9H6O3]−, 179.0358[M−H−C9H6O3−H2O]−, 161.0247[M−H−C9H6O3−2H2O]−, 123.0419[M−H−C11H8O6]− | Rosmarinic acid | ||
| 38.19 | C12H14O3 | 207.1018 (0.9) | 189.0890[M+H−H2O]+, 179.1067[M+H−CO]+, 165.0873[M+H−C2H2O]+, 161.0943[M+H−H2O−CO]+ | Senkyunolide F | ||
| 38.71 | C26H22O10 | 493.1151 (2.2) | 295.0623123.0419[M−H−C9H10O5]−, 159.0453[M−H−C9H10O5−C8H8O2]−, 109.0290[M−H−C9H10O5−C11H6O3]− | Salvianolic acid A | ||
| 40.71 | C22H22O9 | 431.1338 (0.2) | 269.0813[M+H−C6H10O5]+, 254.0563[M+H−C6H10O5−CH3]+, 237.0533[M+H−C6H10O5−CH3OH]+, 213.0902[M+H−C6H10O5−2CO]+ | Ononin | ||
| 41.36 | C36H30O16 | 719.1602 (−0.7) | 717.1488 (3.2) | 521.0991[M+H−C9H10O5]+, 341.0605[M+H−C9H10O5−C9H8O4]+, 323.0536[M+H−2C9H10O5]+ | 519.0952[M−H−C9H10O5]−, 339.0531[M−H−C9H10O5−C9H8O4]−, 321.0413[M−H−2C9H10O5]−, 295.0630[M−H−C9H10O5−C9H8O4−CO2]−, 279.0307[M−H−2C9H10O5−C2H2O]− | Salvianolic acid B |
| 45.27 | C16H12O5 | 285.0760 (0.9) | 283.0620 (3) | 270.0516[M+H−CH3]+, 253.0470[M+H−CH3OH]+, 225.0540[M+H−CH3OH−CO]+, 197.0580[M+H−CH3OH−2CO]+, 137.0245[M+H−C9H8O5]+ | 268.0385[M−H−CH3]−, 195.0483[M−H−CH3OH−2CO]−, 135.0056[M−H−C9H8O5]− | Calycosin |
| 46.93 | C17H16O5 | 301.1073 (0.9) | 299.0933 (2.7) | 167.0714[M+H−C8H6O2]+, | (6aR,11aR)-3-Hydroxy-9,10-dimethoxypterocarpan | |
| 48.25 | C30H32O12 | 583.1829 (1.4) | 165.0501[M−H−C24H18O7]−, 121.0278[M−H−C23H26O10]− | Benzoylpaeoniflorin | ||
| 49.21 | C9H8O | 133.0648 (0.4) | 115.0581[M+H−H2O]+, 105.0755[M+H−CO]+, 91.0609[M+H−C2H2O]+, 77.0468[M+H−C3H4O]+ | Cinnamaldehyde | ||
| 51.46 | C43H42O22 | 909.2125 (3.3) | 501.1065[M−H−C19H20O10]−, 407.0936[M−H−C24H22O12]− | Carthamin | ||
| 53.9 | C42H66O14 | 793.4401 (2.7) | 631.3946[M−H−C6H10O5]− | Chikusetsusaponin IVa | ||
| 54.24 | C47H72O20 | 955.4577 (3.4) | 835.4515[M−H−C4H8O4]−, 793.4461[M−H−C6H10O5]− | Achyranthoside C | ||
| 54.26 | C47H70O20 | 953.4443 (4.8) | 909.4571[M−H−CO2]−, 851.4411[M−H−C4H8O4]−, 793.4462[M−H−C5H4O6]− | Achyranthoside A | ||
| 54.46 | C12H14O3 | 205.0874 (2.1) | 161.0962[M−H−CO2]− | 3-Butyl-4-hydroxyphthalide | ||
| 54.82 | C16H12O4 | 269.0810 (0.8) | 267.0666 (1.3) | 254.0567[M+H−CH3]+, 237.0527[M+H−CH3OH]+, 213.0892[M+H−2CO]+ | 252.0428[M−H−CH3]+ | Formononetin |
| 60.83 | C19H18O4 | 311.1281 (1) | 267.1380[M+H−CO2]+ | Hydroxytanshinone IIA | ||
| 62.89 | C12H16O2 | 193.1225 (0.9) | 147.1187[M+H−H2O−CO]+, 137.0624[M+H−C4H8]+, 105.0745[M+H−H2O−CO−C3H6]+, 91.0606[M+H−H2O−CO−C4H8]+ | Senkyunolide A | ||
| 67.87 | C12H18O2 | 195.1378 (−0.7) | 177.1309[M+H−H2O]+, 149.1345[M+H−H2O−CO]+ | Neocnidilide | ||
| 68.04 | C18H14O3 | 279.1018 (0.8) | 261.0910[M+H−H2O]+, 233.0959[M+H−H2O−CO]+, 205.1012[M+H−H2O−2CO]+, 190.0776[M+H−H2O−2CO−CH3]+ | Dihydrotanshinone I | ||
| 68.42 | C12H14O2 | 191.1066 (−0.4) | 173.0976[M+H−H2O]+, 163.1125[M+H−C2H4]+, 155.0866[M+H−2H2O]+, 149.0612[M+H−C3H6]+, 145.1029[M+H−H2O−CO]+, 135.0462[M+H−C4H8]+ | Ligustilide | ||
| 70.72 | C20H18O5 | 339.1230 (1) | 279.1003[M+H−C2H4O2]+, 261.0908[M+H−C2H4O2−H2O]+, 233.0956[M+H−C2H4O2−H2O−CO]+, 205.0994[M+H−C2H4O2−H2O−2CO]+, 190.0763[M+H−C2H4O2−H2O−2CO−CH3]+ | Methyl tanshinonate | ||
| 74.36 | C19H20O3 | 297.1492 (2.1) | 279.1372[M+H−H2O]+, 268.1080[M+H−C2H4]+, 251.1422[M+H−H2O−CO]+, 237.0896[M+H−H2O−C3H6]+, 209.0957[M+H−H2O−C5H10]+ | Cryptotanshinone | ||
| 74.79 | C18H32O3 | 295.2292 (3.9) | 277.2176[M−H−H2O]−, 195.1400[M−H−C6H12O]− | 13-Hydroxy-9,11-hexadecadienoic acid | ||
| 75.02 | C18H12O3 | 277.0862 (0.8) | 249.0908[M+H−CO]+, 231.0756[M+H−CO−H2O]+, 221.0990[M+H−C3H4O]+, 193.1013[M+H−2CO]+ | Tanshinone I | ||
| 83.42 | C24H28O4 | 381.2063 (0.2) | 191.1069[M+H−C12H14O2]+, 173.0970[M+H−C12H14O2−H2O]+, 149.0623[M+H−C12H14O2−C3H6]+, 135.0470[M+H−C12H14O2−C4H8]+ | Levistilide A | ||
| 84.62 | C19H18O3 | 295.1335 (0.9) | 280.1076[M+H−CH3]+, 277.1222[M+H−H2O]+, 262.0984[M+H−CH3−H2O]+, 249.1267[M+H−H2O−CO]+ | Tanshinone IIA | ||
| 87.2 | C19H22O2 | 283.1695 (0.9) | 265.1598[M+H−H2O]+, 223.1107[M+H−H2O−C3H6]+, 207.1137[M+H−H2O−C3H6−CH3]+ | Miltirone | ||
| 97.22 | C18H35NO | 282.2796 (1.5) | 265.2540[M+H−NH3]+, 247.2422[M+H−H2O−NH3]+ | (Z)-9-Octadecenamide | ||
| 100.6 | C32H48O5 | 513.3578 (0.7) | 407.3295[M+H−CH2O2−C2H4O2]+, 173.1321[M+H−C25H24O]+ | Acetyl-11-keto-β-boswellic acid |
Changes of body weight in different groups.
| Time (months) | Normal group | Model group | NXT group |
|---|---|---|---|
| 0 | 13.97 ± 0.80 | 15.83 ± 1.63 | 15.73 ± 0.93 |
| 1 | 17.43 ± 1.24 | 17.20 ± 0.72 | 15.43 ± 1.97 |
| 2 | 21.40 ± 1.25 | 25.03 ± 1.52 | 21.17 ± 2.47 |
| 3 | 26.10 ± 3.86 | 32.17 ± 1.53 | 25.73 ± 2.77 |
| 4 | 34.20 ± 1.73 | 44.87 ± 1.50** | 33.73 ± 1.70# |
| 5 | 40.63 ± 1.38 | 51.93 ± 1.76** | 42.90 ± 2.10## |
| 6 | 45.43 ± 2.10 | 57.13 ± 1.75** | 51.67 ± 3.23## |
| 7 | 50.83 ± 1.15 | 62.90 ± 1.57** | 60.00 ± 2.76 |
| 8 | 54.53 ± 0.61 | 71.23 ± 1.99** | 68.57 ± 0.80 |
Data represent mean ± SD. **P < 0.01 vs. normal group. #P < 0.05 vs. model group. ##P < 0.01 vs. model group. n = 3.
Figure 1Changes in serum cholesterol (T-CHO) (A), triglyceride (TG) (B), low density lipoprotein (LDL-C), (C) and high-density lipoprotein (HDL-C) (D). Data represent mean ± SD. *P < 0.05 vs. normal group. **P < 0.01 vs. normal group. #P < 0.05 vs. model group. ##P < 0.01 vs. model group. n = 3.
Figure 2Changes in glutamic–oxalacetic transaminase (AST) (A), glutamic–pyruvic transaminase (ALT) (B), creatinine (Cr) (C), urea nitrogen (BUN) (D), uric acid (UA) (E). Data represent mean ± SD. *P < 0.05 vs. normal group. **P < 0.01 vs. normal group. #P < 0.05 vs. model group. ##P < 0.01 vs. model group. n = 3.
Figure 3Changes in methane dicarboxylic aldehyde (MDA) (A), superoxide dismutase (SOD) (B). Data represent mean ± SD. *P < 0.05 vs. normal group. **P < 0.01 vs. normal group. #P < 0.05 vs. model group. ##P < 0.01 vs. model group. n = 3.
Figure 4Changes in interleukin-6 (IL-6) (A), interleukin-1β (IL-1β) (B), tumor necrosis factor-α (TNF-α) (C), and interleukin-8 (IL-8) (D). Data represent mean ± SD. *P < 0.05 vs. normal group. **P < 0.01 vs. normal group. #P < 0.05 vs. model group. ##P < 0.01 vs. model group. n = 3.
Figure 5Changes in creatine kinase-MB (A) and lactic dehydrogenase (B). Data represent mean ± SD. *P < 0.05 vs. normal group. **P < 0.01 vs. normal group. #P < 0.05 vs. model group. ##P < 0.01 vs. model group. n = 3.
Figure 6Pathological observations with hematoxylin-eosin (HE) staining on heart (A-C), carotid artery (D-F), abdominal aorta (G-I), and coronary artery (J-L) of minipigs in each group.
Figure 7Box chart of alpha diversity between groups.
Figure 8Beta diversity changes due to the NXT treatment. Samples of the same color belong to the same group (green, NXT group; blue, model group; red, normal group). The closer the samples are, indicating that the more similar the composition of the samples.
Figure 9Relative abundances of different bacteria at phylum level of each group (A) and each animal (B).
Figure 10Effect of NXT on the recovery of dysbiosis of gut microbiota (A) and key bacteria (B) at genus level. For (A), the higher red degree means the less the relative abundance, while the higher green degree means the more the relative abundance. For (B), data represent mean ± SD. *P < 0.05 vs. normal group. #P < 0.05 vs. model group.
Figure 11The correlation heatmap of identifying associations between the gut microbiota structure (genus level) and the pathological indexes. The red color means positive correlation while the blue color shows a negative correlation. The deeper color means the greater correlation (p < 0.05*, p < 0.01**).
Figure 12Associations between the gut microbiota (NXT significantly affect) and the pathological indexes. Associations with the pathological indexes are shown for each genus microbiota with the direction of correlation indicated by red (positive) or blue (negative) lines.